

# Bethan Sarah Woods

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6066050/publications.pdf>

Version: 2024-02-01

17  
papers

802  
citations

1163117

8  
h-index

888059

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1856  
citing authors

#	ARTICLE	IF	CITATIONS
1	Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. <i>Value in Health</i> , 2016, 19, 929-935.	0.3	589
2	Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. <i>PLoS ONE</i> , 2017, 12, e0172749.	2.5	51
3	Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. <i>Heart</i> , 2016, 102, 1742-1749.	2.9	30
4	Acupuncture for chronic pain and depression in primary care: a programme of research. <i>Programme Grants for Applied Research</i> , 2017, 5, 1-316.	1.0	27
5	Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. <i>Value in Health</i> , 2021, 24, 1828-1834.	0.3	22
6	â€œArmâ€¢basedâ€¢ parameterization for network metaâ€¢analysis. <i>Research Synthesis Methods</i> , 2016, 7, 306-313.	8.7	17
7	Simulation Modeling and Metamodeling to Inform National and International HIV Policies for Children and Adolescents. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, S49-S57.	2.1	12
8	Methods for network meta-analysis of continuous outcomes using individual patient data: a case study in acupuncture for chronic pain. <i>BMC Medical Research Methodology</i> , 2016, 16, 131.	3.1	11
9	Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2649-2666.	1.7	8
10	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. <i>Journal of Medical Economics</i> , 2017, 20, 8-18.	2.1	7
11	Appraising the value of evidence generation activities: an HIV modelling study. <i>BMJ Global Health</i> , 2018, 3, e000488.	4.7	7
12	Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?. <i>Pharmacoeconomics</i> , 2016, 34, 427-433.	3.3	6
13	Classifying information-sharing methods. <i>BMC Medical Research Methodology</i> , 2021, 21, 107.	3.1	6
14	Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 981-992.	3.3	4
15	Practical metrics for establishing the health benefits of research to support research prioritisation. <i>BMJ Global Health</i> , 2020, 5, e002152.	4.7	3
16	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 19-19.	1.6	1
17	Concomitant health benefits package design and research prioritisation: development of a new approach and an application to Malawi. <i>BMJ Global Health</i> , 2021, 6, e007047.	4.7	1